表紙
市場調查報告書

藥物安全檢測的全球市場 (各臨床實驗階段,服務業者,各地區):市場規模,產業分析,今後展望·成長可能性,價格趨勢,市場佔有率,未來預測

Pharmacovigilance Market Size By Clinical Trial Phase, By Service Provider, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025

出版商 Global Market Insights Inc. 商品編碼 622789
出版日期 內容資訊 英文 165 Pages
商品交期: 2-3個工作天內
價格
藥物安全檢測的全球市場 (各臨床實驗階段,服務業者,各地區):市場規模,產業分析,今後展望·成長可能性,價格趨勢,市場佔有率,未來預測 Pharmacovigilance Market Size By Clinical Trial Phase, By Service Provider, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025
出版日期: 2019年12月18日內容資訊: 英文 165 Pages
簡介

本報告提供全球藥物安全檢測 (醫藥品安全性監視)的市場相關分析,提供產業的基本結構和向心力,技術·法規環境,主要的推動及阻礙市場要素,臨床實驗階段 (各期/階段) ·服務供應商·各地區的市場趨勢預測 (過去4年·今後8年份),主要企業的簡介·業績·策略等調查。

第1章 分析方法與市場範圍

第2章 摘要整理

第3章 數位Health產業分析

  • 產業區分
  • 產業形勢 (總計12年)
  • 產業的影響要素
    • 成長促進因素
    • 產業的陷阱與課題
  • 成長可能性分析
    • 各臨床實驗階段 (各期,階段)
    • 服務業者的各類型
    • 新的經營模式
  • 波特的五力分析
  • 法規環境
  • 藥物安全檢測的報告系統
  • 企業佔有率分析
    • 市場策略一覽
  • 藥物安全檢測·服務的市場環境
  • PESTEL分析

第4章 藥物安全檢測市場:各臨床實驗階段

  • 市場主要趨勢:臨床實驗階段 (各期)
  • 前臨床
    • 市場規模的實際成果值·預測值:各地區 (總計12年份)
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章 藥物安全檢測市場:服務業者

  • 市場主要趨勢:服務業者
  • 公司內部部門
  • 外部委託業者

第6章 藥物安全檢測市場:各地區

  • 市場主要趨勢
  • 北美 (美國,加拿大)
    • 市場規模的實際成果值·預測值:各國 (總計12年份)
    • 市場規模的實際成果值·預測值:各臨床實驗階段 (總計12年份)
    • 市場規模的實際成果值·預測值:服務業者 (總計12年份)
  • 歐洲 (德國,英國,西班牙,義大利,法國)
  • 亞太地區 (日本,中國,印度,澳洲)
  • 南美 (阿根廷,巴西,墨西哥)
  • 中東·非洲 (南非,UAE,沙烏地阿拉伯,卡達,以色列)

第7章 企業簡介

  • Accenture
    • 產業概要,財務資料,產品概要,策略部署預測,SWOT分析
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • Ecron Acunova Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Foresight Group International AG
  • GlaxoSmithKline Plc.
  • HCL Technologies
  • IBM Corporation
  • ICON plc
  • iGATE Corporation (Capgemini)
  • Infosys Ltd.
  • InVentiv Health Clinical
  • Ipca Laboratories Ltd.
  • IQVIA (QuintilesIMS)
  • Itclinical
  • Janssen Research & Development, LLC
  • Laboratory Corporation of America Holdings
  • Novartis AG
  • Oracle Corporation
  • Parexel International Corporation
  • Pfizer
  • Sanofi Aventis
  • TCS
  • Telerx (C3i Solutions)
  • Wipro

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 853

Title:
Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract Outsourcing), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025.

Pharmacovigilance market is expected to exceed USD 8.9 billion by 2025. The increasing drug consumption and growing concerns regarding adverse drug effects across the globe will drive market growth over the analysis timeframe.

Some major findings of the pharmacovigilance market report include:

Growing adoption of personalized medicines and increasing demand for targeted drugs will drive the demand for pharmacovigilance services

Need of pharmacovigilance for effective surveillance of adverse drug reactions will render several growth opportunities

Contract outsourcing segment to witness significant growth owing to reduced operational costs, efficient monitoring through regulatory compliance, enhanced productivity and higher quality provided by outsourcing companies

Industry players operating in the pharmacovigilance market such as Cognizant, TCS, Accenture, IQVIA and ICON among others, adopt various organic and inorganic growth strategies to capitalize on market opportunities

Growing prevalence of chronic diseases, increasing accessibility to drugs and rising per capita healthcare expenditure in various countries across the globe will serve to be major impact rendering factors for the pharmacovigilance industry growth. The consumption of drugs is increasing day by day, wherein, a large proportion of prescription drugs is abused. According to the Centers for Disease Control and Prevention, in 2017, over 28,000 deaths occurred due to consumption of synthetic opioids in the U.S. Increasing drug consumption and concerns regarding adverse drug reactions will surge the demand for pharmacovigilance activities in the coming years.

Moreover, adoption of personalized medicines is growing considerably, especially in the developed nations. Growing adoption of gene therapy in the treatment of different types of cancer and other chronic diseases, will surge the demand for personalized medicines over the forecast period. Advances in personalized and precision medicine are anticipated to offer highly specific solutions to individuals by considering their genetic composition and its reactions to medicine. Innovations in personalized medicine and its growing acceptance will escalate the need for pharmacovigilance practices.

The clinical trial phases segment is divided into preclinical studies, phase I, phase II, phase III and phase IV. Phase IV pharmacovigilance segment held significant revenue share of more than 70% in 2018. Pharmacovigilance is vital for safety surveillance after the drug is released in the market. It detects and reports any adverse drug reactions (ADRs) & harmful effects that may result into discontinuation of drugs or may be limited for use in certain patients. Thus, increasing number of pharmaceutical companies focusing on new drug development will positively impact the business growth.

The service providers segment is bifurcated into in-house and contract outsourcing. In-house services segment held around 45% revenue share in 2018 and is estimated to grow considerably over the forecast timeframe. Concerns regarding data safety and confidentiality will increase the preference towards in-house pharmacovigilance services. Moreover, presence of companies with skilled staff and developed infrastructure will further favor segmental growth. However, less cost-effectivity and dearth of expertise can be a potential challenge that may impede segmental growth in certain developing and underdeveloped countries.

Europe pharmacovigilance market is projected to experience over 9.5% CAGR during the analysis period. High centralization and harmonization of pharmacovigilance practices will lead to more effective detection of safety signals in the Europe. New regulations for pharmacovigilance imposed in the European Union (EU) since July 2012, has led to increased involvement of healthcare professionals and patients in the Pharmacovigilance and Risk Assessment Committee (PRAC). Moreover, evolution in personalized medicines will offer ample opportunities for the regional market growth.

Some of the notable industry players operating in the pharmacovigilance market include Accenture, Clinquest Group, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Cognizant, Ecron Acunova Ltd, F. Hoffmann-La Roche Ltd, IQVIA, HCL Technologies, IBM Corporation, ICON and Infosys Ltd. These industry players resort to acquisitions, mergers and new product launch to sustain market positions. For instance, in May 2015, Pfizer introduced Reportum, a pharmacovigilance solution developed by MyMeds&Me, in the U.S. market. Reportum is deployed across all Pfizer safety call centers in the U.S. and helps in collection of data related to adverse events.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definitions
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Pharmacovigilance industry 360 degree synopsis, 2014 - 2025
    • 2.1.1. Business trends
    • 2.1.2. Clinical trial phase trends
    • 2.1.3. Service provider trends
    • 2.1.4. Regional trends

Chapter 3. Pharmacovigilance Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2014 - 2025
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
      • 3.3.1.1. Growth in adoption rate of outsourcing services in Asia Pacific
      • 3.3.1.2. Increasing consumption of drugs in developed regions
      • 3.3.1.3. Rise in adverse drug reactions (ADR) and drug toxicity
      • 3.3.1.4. Increasing acceptance of personalized medicine in developed regions
      • 3.3.1.5. Effective global harmonization practices
    • 3.3.2. Industry pitfalls and challenges
      • 3.3.2.1. Dearth of skilled personnel
      • 3.3.2.2. High risk associated with data security
  • 3.4. Growth potential analysis
    • 3.4.1. By clinical trial phase
    • 3.4.2. By service provider
  • 3.5. New business models
  • 3.6. Regulatory landscape
  • 3.7. Pharmacovigilance reporting system
  • 3.8. Porter's analysis
  • 3.9. Competitive landscape, 2018
    • 3.9.1. Strategy dashboard
  • 3.10. PESTEL analysis

Chapter 4. Pharmacovigilance Market, By Clinical Trial Phase

  • 4.1. Key segment trends
  • 4.2. Preclinical
    • 4.2.1. Market size, by region, 2014 - 2025 (USD Million)
  • 4.3. Phase I
    • 4.3.1. Market size, by region, 2014 - 2025 (USD Million)
  • 4.4. Phase II
    • 4.4.1. Market size, by region, 2014 - 2025 (USD Million)
  • 4.5. Phase III
    • 4.5.1. Market size, by region, 2014 - 2025 (USD Million)
  • 4.6. Phase IV
    • 4.6.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 5. Pharmacovigilance Market, By Service Provider

  • 5.1. Key segment trend
  • 5.2. In-house
    • 5.2.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.3. Contract resourcing
    • 5.3.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 6. Pharmacovigilance Market, By Region

  • 6.1. Key regional market
  • 6.2. North America
    • 6.2.1. Market size, by country, 2014 - 2025 (USD Million)
    • 6.2.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
    • 6.2.3. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.2.4. U.S.
      • 6.2.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.2.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.2.5. Canada
      • 6.2.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.2.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
  • 6.3. Europe
    • 6.3.1. Market size, by country, 2014 - 2025 (USD Million)
    • 6.3.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
    • 6.3.3. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.3.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.3.5. UK
      • 6.3.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.3.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.3.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.3.7. Italy
      • 6.3.7.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.3.7.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.3.8. France
      • 6.3.8.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.3.8.2. Market size, by service provider, 2014 - 2025 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Market size, by country, 2014 - 2025 (USD Million)
    • 6.4.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
    • 6.4.3. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.4.4. Japan
      • 6.4.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.4.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.4.5. China
      • 6.4.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.4.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.4.6. India
      • 6.4.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.4.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.4.7. Australia
      • 6.4.7.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.4.7.2. Market size, by service provider, 2014 - 2025 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Market size, by country, 2014 - 2025 (USD Million)
    • 6.5.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
    • 6.5.3. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.5.4. Argentina
      • 6.5.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.5.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.5.5. Brazil
      • 6.5.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.5.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.5.6. Mexico
      • 6.5.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.5.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
  • 6.6. MEA
    • 6.6.1. Market size, by country, 2014 - 2025 (USD Million)
    • 6.6.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
    • 6.6.3. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.6.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.6.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.6.6. Saudi Arabia
      • 6.6.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.6.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.6.7. Qatar
      • 6.6.7.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.6.7.2. Market size, by service provider, 2014 - 2025 (USD Million)
    • 6.6.8. Israel
      • 6.6.8.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
      • 6.6.8.2. Market size, by service provider, 2014 - 2025 (USD Million)

Chapter 7. Company Profiles

  • 7.1. Accenture
    • 7.1.1. Business overview
    • 7.1.2. Financial data
    • 7.1.3. Service landscape
    • 7.1.4. Strategic outlook
    • 7.1.5. SWOT analysis
  • 7.2. Boehringer Ingelheim
    • 7.2.1. Business overview
    • 7.2.2. Financial data
    • 7.2.3. Service landscape
    • 7.2.4. Strategic outlook
    • 7.2.5. SWOT analysis
  • 7.3. Bristol-Myers Squibb
    • 7.3.1. Business overview
    • 7.3.2. Financial data
    • 7.3.3. Service landscape
    • 7.3.4. Strategic outlook
    • 7.3.5. SWOT analysis
  • 7.4. Clinquest Group B.V.
    • 7.4.1. Business overview
    • 7.4.2. Financial data
    • 7.4.3. Service landscape
    • 7.4.4. Strategic outlook
    • 7.4.5. SWOT analysis
  • 7.5. Cognizant Technology Solutions Corporation
    • 7.5.1. Business overview
    • 7.5.2. Financial data
    • 7.5.3. Service landscape
    • 7.5.4. Strategic outlook
    • 7.5.5. SWOT analysis
  • 7.6. Ecron Acunova Ltd.
    • 7.6.1. Business overview
    • 7.6.2. Financial data
    • 7.6.3. Service landscape
    • 7.6.4. Strategic outlook
    • 7.6.5. SWOT analysis
  • 7.7. F. Hoffmann-La Roche Ltd.
    • 7.7.1. Business overview
    • 7.7.2. Financial data
    • 7.7.3. Service landscape
    • 7.7.4. Strategic outlook
    • 7.7.5. SWOT analysis
  • 7.8. GlaxoSmithKline
    • 7.8.1. Business overview
    • 7.8.2. Financial data
    • 7.8.3. Service landscape
    • 7.8.4. Strategic outlook
    • 7.8.5. SWOT analysis
  • 7.9. HCL Technologies
    • 7.9.1. Business overview
    • 7.9.2. Financial data
    • 7.9.3. Service landscape
    • 7.9.4. Strategic outlook
    • 7.9.5. SWOT analysis
  • 7.10. IBM Corporation
    • 7.10.1. Business overview
    • 7.10.2. Financial data
    • 7.10.3. Service landscape
    • 7.10.4. Strategic outlook
    • 7.10.5. SWOT analysis
  • 7.11. ICON plc
    • 7.11.1. Business overview
    • 7.11.2. Financial data
    • 7.11.3. Service landscape
    • 7.11.4. Strategic outlook
    • 7.11.5. SWOT analysis
  • 7.12. iGATE Corporation (Capgemini)
    • 7.12.1. Business overview
    • 7.12.2. Financial data
    • 7.12.3. Service landscape
    • 7.12.4. Strategic outlook
    • 7.12.5. SWOT analysis
  • 7.13. Infosys Ltd.
    • 7.13.1. Business overview
    • 7.13.2. Financial data
    • 7.13.3. Service landscape
    • 7.13.4. Strategic outlook
    • 7.13.5. SWOT analysis
  • 7.14. InVentiv Health Clinical
    • 7.14.1. Business overview
    • 7.14.2. Financial data
    • 7.14.3. Service landscape
    • 7.14.4. Strategic outlook
    • 7.14.5. SWOT analysis
  • 7.15. Ipca Laboratories Ltd.
    • 7.15.1. Business overview
    • 7.15.2. Financial data
    • 7.15.3. Service landscape
    • 7.15.4. Strategic outlook
    • 7.15.5. SWOT analysis
  • 7.16. IQVIA (QuintilesIMS)
    • 7.16.1. Business overview
    • 7.16.2. Financial data
    • 7.16.3. Service landscape
    • 7.16.4. Strategic outlook
    • 7.16.5. SWOT analysis
  • 7.17. ITclinical
    • 7.17.1. Business overview
    • 7.17.2. Financial data
    • 7.17.3. Service landscape
    • 7.17.4. Strategic outlook
    • 7.17.5. SWOT analysis
  • 7.18. Janssen Research & Development, LLC
    • 7.18.1. Business overview
    • 7.18.2. Financial data
    • 7.18.3. Service landscape
    • 7.18.4. Strategic outlook
    • 7.18.5. SWOT analysis
  • 7.19. Laboratory Corporation of America Holdings
    • 7.19.1. Business overview
    • 7.19.2. Financial data
    • 7.19.3. Service landscape
    • 7.19.4. Strategic outlook
    • 7.19.5. SWOT analysis
  • 7.20. Novartis AG
    • 7.20.1. Business overview
    • 7.20.2. Financial data
    • 7.20.3. Service landscape
    • 7.20.4. Strategic outlook
    • 7.20.5. SWOT analysis
  • 7.21. Oracle Corporation
    • 7.21.1. Business overview
    • 7.21.2. Financial data
    • 7.21.3. Service landscape
    • 7.21.4. Strategic outlook
    • 7.21.5. SWOT analysis
  • 7.22. PAREXEL International Corporation
    • 7.22.1. Business overview
    • 7.22.2. Financial data
    • 7.22.3. Service landscape
    • 7.22.4. Strategic outlook
    • 7.22.5. SWOT analysis
  • 7.23. Pfizer
    • 7.23.1. Business overview
    • 7.23.2. Financial data
    • 7.23.3. Service landscape
    • 7.23.4. Strategic outlook
    • 7.23.5. SWOT analysis
  • 7.24. Sanofi Aventis
    • 7.24.1. Business overview
    • 7.24.2. Financial data
    • 7.24.3. Service landscape
    • 7.24.4. Strategic outlook
    • 7.24.5. SWOT analysis
  • 7.25. TCS
    • 7.25.1. Business overview
    • 7.25.2. Financial data
    • 7.25.3. Service landscape
    • 7.25.4. Strategic outlook
    • 7.25.5. SWOT analysis
  • 7.26. Wipro
    • 7.26.1. Business overview
    • 7.26.2. Financial data
    • 7.26.3. Service landscape
    • 7.26.4. Strategic outlook
    • 7.26.5. SWOT analysis

Data Tables

  • TABLE 1. Pharmacovigilance industry 360 degree synopsis, 2014 - 2025
  • TABLE 2. Pharmacovigilance market, 2014-2018 (USD Million)
  • TABLE 3. Pharmacovigilance market, 2019-2025 (USD Million)
  • TABLE 4. Pharmacovigilance market, by clinical trial phase, 2014-2018 (USD Million)
  • TABLE 5. Pharmacovigilance market, by clinical trial phase, 2019-2025 (USD Million)
  • TABLE 6. Pharmacovigilance market, by service provider, 2014-2018 (USD Million)
  • TABLE 7. Pharmacovigilance market, by service provider, 2019-2025 (USD Million)
  • TABLE 8. Pharmacovigilance market, by region, 2014-2018 (USD Million)
  • TABLE 9. Pharmacovigilance market, by region, 2019-2025 (USD Million)
  • TABLE 10. Industry impact forces
  • TABLE 11. Pharmacovigilance regulatory initiatives
  • TABLE 12. Preclinical market size, by region, 2014-2025 (USD Million)
  • TABLE 13. Phase I market size, by region, 2014-2025 (USD Million)
  • TABLE 14. Phase II market size, by region, 2014-2025 (USD Million)
  • TABLE 15. Phase III market size, by region, 2014-2025 (USD Million)
  • TABLE 16. Phase IV market size, by region, 2014-2025 (USD Million)
  • TABLE 17. In-house market size, by region, 2014-2025 (USD Million)
  • TABLE 18. Contract outsourcing market size, by region, 2014-2025 (USD Million)
  • TABLE 19. North America pharmacovigilance market size, by country, 2014-2025 (USD Million)
  • TABLE 20. North America pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 21. North America pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 22. U.S. pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 23. U.S. pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 24. Canada pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 25. Canada pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 26. Europe pharmacovigilance market size, by country, 2014-2025 (USD Million)
  • TABLE 27. Europe pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 28. Europe pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 29. Germany pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 30. Germany pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 31. UK pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 32. UK pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 33. Spain pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 34. Spain pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 35. Italy pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 36. Italy pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 37. France pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 38. France pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 39. Asia Pacific pharmacovigilance market size, by country, 2014-2025 (USD Million)
  • TABLE 40. Asia Pacific pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 41. Asia Pacific pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 42. Japan pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 43. Japan pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 44. China pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 45. China pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 46. India pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 47. India pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 48. Australia pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 49. Australia pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 50. Latin America pharmacovigilance market size, by country, 2014-2025 (USD Million)
  • TABLE 51. Latin America pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 52. Latin America pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 53. Argentina pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 54. Argentina pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 55. Brazil pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 56. Brazil pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 57. Mexico pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 58. Mexico pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 59. MEA pharmacovigilance market size, by country, 2014-2025 (USD Million)
  • TABLE 60. MEA pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 61. MEA pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 62. South Africa pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 63. South Africa pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 64. UAE pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 65. UAE pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 66. Saudi Arabia pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 67. Saudi Arabia pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 68. Qatar pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 69. Qatar pharmacovigilance market size, by service provider, 2014-2025 (USD Million)
  • TABLE 70. Israel pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million)
  • TABLE 71. Israel pharmacovigilance market size, by service provider, 2014-2025 (USD Million)

Charts & Figures

  • FIG 1. Industry segmentation
  • FIG 2. Global pharmacovigilance market, 2014 - 2025 (USD Million)
  • FIG 3. Growth potential analysis, by clinical trial phase
  • FIG 4. Growth potential analysis, by service provider
  • FIG 5. Types of pharmacovigilance outsourcing vendors
  • FIG 6. Porter's analysis
  • FIG 7. Company market share analysis, 2018
  • FIG 8. Strategy dashboard
  • FIG 9. PESTEL analysis